Daiichi Sankyo Company has received Japanese approval to manufacture and market new formulation of Cravit (levofloxacin hydrate) intravenous injections.
The fluoroquinolone intravenous anti-bacterial agent comes in 500mg/100ml IV bags and 500mg/20ml injections (Cravit IV).
Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections.
The treatment has already been approved in 120 different countries and territories, and has been very well received, Daiichi Sankyo said.
In Japan, orally administered 100mg Cravit tablets were approved for sale in December 1993 and in July 2009, the once-daily administration with 500mg Cravit was approved in line with the world standard dosage regimen.
Now, Daiichi Sankyo has further expanded treatment options with the addition of Cravit IV.